<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545464</url>
  </required_header>
  <id_info>
    <org_study_id>P160913</org_study_id>
    <nct_id>NCT03545464</nct_id>
  </id_info>
  <brief_title>COrticosteroids in acUte uRticAria in emerGency dEpartment</brief_title>
  <acronym>COURAGE</acronym>
  <official_title>COrticosteroids in acUte uRticAria in emerGency dEpartment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the non-inferiority of the efficacy of a single antihistamine in comparaison&#xD;
      with an association of antihistamine and corticosteroid in the treatment of acute urticaria&#xD;
      in emergency departments&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute urticaria (hives) is a common skin disease. The prevalence of acute urticaria in life&#xD;
      is about 15 to 20% in the general population. It is responsible for a frequent use of&#xD;
      emergency departments (ED). The usual treatment is based on early administration of an&#xD;
      association of antihistamines and corticosteroid. The therapeutic efficacy of corticosteroids&#xD;
      has never been established by high evidence studies. However, corticosteroids are frequently&#xD;
      used. When stopped, corticosteroids could promote the occurence of urticaria recurrences, and&#xD;
      a transition to chronic urticaria. In addition, corticosteroids may be rarely responsible for&#xD;
      gastrointestinal bleeding, hypertension and diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2019</start_date>
  <completion_date type="Anticipated">March 21, 2022</completion_date>
  <primary_completion_date type="Actual">September 28, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-Days Urticaria Activity Score (UAS 7) at day 7</measure>
    <time_frame>For 7 day</time_frame>
    <description>Urticaria Activity Score (UAS) is a daily combined score of severity of itch and number of hives. Each component of the UAS is scored on a scale of 0 to 3; the 2 scores are added together for a daily total of 0 to 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of hives at day 7 and/or recurrence of itch at day 7</measure>
    <time_frame>For 7 day</time_frame>
    <description>The UAS 7 is the sum of the daily UAS scores over 7 days. This questionnaire will be completed by the patient and the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of spontaneous wheals and/or itch for &gt; 6 weeks</measure>
    <time_frame>beyond 6 Weeks</time_frame>
    <description>wheals and/or itch for &gt; 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with angioedema at day 7, 14 and 3 months</measure>
    <time_frame>up to 3 month</time_frame>
    <description>angioedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The reduction of morbidity is assessed by new emergency visits for acute urticaria recurrences at day 7, 14 and 3 months</measure>
    <time_frame>up to 3 month</time_frame>
    <description>emergency visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(DLQI) up to 6 months</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The DLQI is a dermatology-specific quality of life questionnaire designed for use in patients over 16 years of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cu-Q2QoL up to 6 months</measure>
    <time_frame>at day 7, at day 14, at 6 week, at 3 months and 6 months</time_frame>
    <description>The CU-Q2oL (French version) is a questionnaire that measures the relative burden of chronic urticaria on subjective well-being</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Urticaria</condition>
  <condition>Angiœdema</condition>
  <arm_group>
    <arm_group_label>Antihistamines + placebo of cortancyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- In emergency department : Levocetirizine 5 mg orally. Renewable once if persistence of hives at 30 minutes.&#xD;
Placebo of Cortancyl : 1mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally&#xD;
- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).&#xD;
Placebo of Cortancyl 20 mg x 2 tablets = 40mg once per day for 3 days orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Association of antihistamines and cortancyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>- In emergency department : Levocetirizine 5 mg orally Renewable once if persistence of hives at 30 minutes.&#xD;
Cortancyl: 1 mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally.&#xD;
- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).&#xD;
Cortancyl : 20 mg x 2 tablets = 40 mg per day for 3 days orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo of cortancyl Oral Tablet 20mg</description>
    <arm_group_label>Antihistamines + placebo of cortancyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cortancyl Oral Tablet</intervention_name>
    <description>Cortancyl oral Tablet 20 mg</description>
    <arm_group_label>Association of antihistamines and cortancyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine Oral Tablet</intervention_name>
    <description>Levocetirizine Oral Tablet 5 mg</description>
    <arm_group_label>Antihistamines + placebo of cortancyl</arm_group_label>
    <arm_group_label>Association of antihistamines and cortancyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Isolated acute urticaria (acute hives): spontaneous urticaria, inducible urticaria&#xD;
&#xD;
          -  Acute urticaria with angioedema without laryngeal edema&#xD;
&#xD;
          -  Obtain patient's consent&#xD;
&#xD;
          -  Social security affiliation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Acute hives with anaphylaxis&#xD;
&#xD;
          -  Bradykinin angioedema&#xD;
&#xD;
          -  Angioedema without urticaria (hives)&#xD;
&#xD;
          -  Laryngeal edema with urticaria (hives)&#xD;
&#xD;
          -  Corticosteroid administration in the previous 5 days visiting the emergency department&#xD;
&#xD;
          -  Antihistamines greater than 1 tablet per day in the previous 5 days visiting the ED&#xD;
&#xD;
          -  Other treatment for urticaria : omalizumab, montelukast, ciclosporine A&#xD;
&#xD;
          -  Chronic urticaria before acute urticaria diagnosis&#xD;
&#xD;
          -  Atopic dermatitis&#xD;
&#xD;
          -  Eczema&#xD;
&#xD;
          -  Bullous pemphigoid&#xD;
&#xD;
          -  Acute exanthematous pustulosis&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Gastrointestinal ulcer&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Known allergy to the study drugs or formulation ingredients&#xD;
&#xD;
          -  Known Renal failure defined by creatinine clearance &lt; 10 mL/min or cardiac failure&#xD;
             defined by ejection fraction &lt; 40%.&#xD;
&#xD;
          -  Corticoid use in 5 days prior to randomisation&#xD;
&#xD;
          -  Contra-indication to corticotherapy:&#xD;
&#xD;
          -  Any live vaccine&#xD;
&#xD;
          -  Psychotic states still uncontrolled by treatment limiting the participant's compliance&#xD;
             with the research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas JAVAUD, M.D,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>France Hospital Louis MOURIER Colombes, Ile De France, France, 92700</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas JAVAUD, M.D,Ph.D</last_name>
    <phone>+33 1 47 60 64 42</phone>
    <email>nicolas.javaud@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fréderic ADNET, M.D,Ph.D</last_name>
    <phone>+33 1 48 96 44 08</phone>
    <email>frederic.adnet@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Louis MOURIER</name>
      <address>
        <city>Colombes</city>
        <state>Ile De France</state>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas JAVAUD, M.D, Ph.D</last_name>
      <phone>+33 1 47 60 64 42</phone>
      <email>nicolas.javaud@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute urticaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Levocetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

